Reuters logo
BRIEF-Madrigal Pharmaceuticals initiates Phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia (HEFH)
February 23, 2017 / 1:32 PM / 7 months ago

BRIEF-Madrigal Pharmaceuticals initiates Phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia (HEFH)

Feb 23 (Reuters) - Madrigal Pharmaceuticals Inc

* Madrigal Pharmaceuticals announces the initiation of a Phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia (HEFH) Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below